Dr. Ogunseinde noted, “Developed with SI-BONE in Longview, Texas, the posteromedial technique is designed to transform the treatment of SI joint dysfunction. Its simplicity enables physicians to treat patients using a minimally invasive approach, enhancing both accessibility and efficiency in the OR.”
About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a leading provider of technology for the surgical treatment of sacropelvic disorders. Since 2009, SI-BONE has been at the forefront of minimally invasive SI joint surgery, supporting over 3,900 physicians in performing more than 100,000 sacropelvic procedures worldwide. SI-BONE’s technologies are backed by robust clinical evidence, including two randomized controlled trials and over 135 peerreviewed studies. Building on its expertise in minimally invasive SI joint fusion, SI-BONE has expanded into adjacent areas such as adult deformity, spinopelvic fixation, and pelvic trauma. For more information, visit www.si-bone.com.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
